Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Average Price Target from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average rating of “Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $55.60.

A number of equities research analysts have weighed in on the company. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday. The Goldman Sachs Group raised their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in TARS. Jennison Associates LLC increased its stake in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after purchasing an additional 698,712 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after buying an additional 420,057 shares during the period. Millennium Management LLC grew its position in shares of Tarsus Pharmaceuticals by 1,259.3% during the 2nd quarter. Millennium Management LLC now owns 348,586 shares of the company’s stock valued at $9,475,000 after buying an additional 322,942 shares during the last quarter. Ally Bridge Group NY LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at about $10,587,000. Finally, Vestal Point Capital LP acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth about $7,565,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Up 2.9 %

Shares of Tarsus Pharmaceuticals stock opened at $48.11 on Friday. Tarsus Pharmaceuticals has a 1-year low of $20.08 and a 1-year high of $57.14. The company has a market capitalization of $1.84 billion, a PE ratio of -12.63 and a beta of 1.02. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The business has a 50-day moving average of $50.92 and a 200-day moving average of $38.73.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.